Impact Biomedical IBO
NYSE IBO
$5.14 +0.35 (+7.31%)
At close: Nov 13, 2026 · 4:00 PM EST

Impact Biomedical (IBO) Convertible Debt (2024 - 2025)

Updated

Impact Biomedical (IBO) posted Convertible Debt of $200,000 for Q2 2025, unchanged from the prior quarter.

Analysis

Impact Biomedical (IBO) Convertible Debt (2024 - 2025) Analysis & Trends

At the end of FY2024, Impact Biomedical's Convertible Debt came in at $201,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Impact Biomedical 43.92 Mn 47.11 Mn 15,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 200,000.00
Mar 31, 2025 200,000.00
Dec 31, 2024 201,000.00
API Access

Impact Biomedical Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=IBO&period=max&api_key=YOUR_API_KEY